We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
News & Views

Research Highlights: Pharmacokinetic and dynamic genetic risk factors for QT prolongation with iloperidone therapy

    James M Stevenson

    University of Illinois at Chicago College of Pharmacy, Department of Pharmacy Practice, 833 S Wood St, Room 164 (M/C 886), IL, USA

    Search for more papers by this author

    &
    Jeffrey R Bishop

    * Author for correspondence

    University of Illinois at Chicago College of Pharmacy, Department of Pharmacy Practice, 833 S Wood St, Room 164 (M/C 886), IL, USA.

    Search for more papers by this author

    Email the corresponding author at jbishop@uic.edu

    Published Online:11 Sep 2013https://doi.org/10.2217/pgs.13.123
    Free first page

    References

    • 1  Nielsen J, Graff C, Kanters JK, Toft E, Taylor D, Meyer JM. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs25(6),473–490 (2011).
      Medline CASGoogle Scholar
    • 2  Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J. Clin. Psychopharmacol.28(2 Suppl. 1),S12–S19 (2008).
      Medline CASGoogle Scholar
    • 3  Potkin SG, Preskorn S, Hochfeld M, Meng X. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. J. Clin. Psychopharmacol.33(1),3–10 (2013).
      Medline CASGoogle Scholar
    • 4  Yang P, Kanki H, Drolet B et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation105(16),1943–1948 (2002).
      Medline CASGoogle Scholar
    • 5  Volpi S, Heaton C, Mack K et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol. Psychiatry14(11),1024–1031 (2009).
      Medline CASGoogle Scholar
    • 6  Hondeghem LM. QT prolongation is an unreliable predictor of ventricular arrhythmia. Heart Rhythm5(8),1210–1212 (2008).
      MedlineGoogle Scholar

    References

    • 1  Nielsen J, Graff C, Kanters JK, Toft E, Taylor D, Meyer JM. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs25(6),473–490 (2011).
      Medline CASGoogle Scholar
    • 2  Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J. Clin. Psychopharmacol.28(2 Suppl. 1),S12–S19 (2008).
      Medline CASGoogle Scholar
    • 3  Potkin SG, Preskorn S, Hochfeld M, Meng X. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. J. Clin. Psychopharmacol.33(1),3–10 (2013).
      Medline CASGoogle Scholar
    • 4  Yang P, Kanki H, Drolet B et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation105(16),1943–1948 (2002).
      Medline CASGoogle Scholar
    • 5  Volpi S, Heaton C, Mack K et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol. Psychiatry14(11),1024–1031 (2009).
      Medline CASGoogle Scholar
    • 6  Hondeghem LM. QT prolongation is an unreliable predictor of ventricular arrhythmia. Heart Rhythm5(8),1210–1212 (2008).
      MedlineGoogle Scholar

    References

    • 1  Nielsen J, Graff C, Kanters JK, Toft E, Taylor D, Meyer JM. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs25(6),473–490 (2011).
      Medline CASGoogle Scholar
    • 2  Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J. Clin. Psychopharmacol.28(2 Suppl. 1),S12–S19 (2008).
      Medline CASGoogle Scholar
    • 3  Potkin SG, Preskorn S, Hochfeld M, Meng X. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. J. Clin. Psychopharmacol.33(1),3–10 (2013).
      Medline CASGoogle Scholar
    • 4  Yang P, Kanki H, Drolet B et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation105(16),1943–1948 (2002).
      Medline CASGoogle Scholar
    • 5  Volpi S, Heaton C, Mack K et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol. Psychiatry14(11),1024–1031 (2009).
      Medline CASGoogle Scholar
    • 6  Hondeghem LM. QT prolongation is an unreliable predictor of ventricular arrhythmia. Heart Rhythm5(8),1210–1212 (2008).
      MedlineGoogle Scholar

    References

    • 1  Nielsen J, Graff C, Kanters JK, Toft E, Taylor D, Meyer JM. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs25(6),473–490 (2011).
      Medline CASGoogle Scholar
    • 2  Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J. Clin. Psychopharmacol.28(2 Suppl. 1),S12–S19 (2008).
      Medline CASGoogle Scholar
    • 3  Potkin SG, Preskorn S, Hochfeld M, Meng X. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. J. Clin. Psychopharmacol.33(1),3–10 (2013).
      Medline CASGoogle Scholar
    • 4  Yang P, Kanki H, Drolet B et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation105(16),1943–1948 (2002).
      Medline CASGoogle Scholar
    • 5  Volpi S, Heaton C, Mack K et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol. Psychiatry14(11),1024–1031 (2009).
      Medline CASGoogle Scholar
    • 6  Hondeghem LM. QT prolongation is an unreliable predictor of ventricular arrhythmia. Heart Rhythm5(8),1210–1212 (2008).
      MedlineGoogle Scholar